TY - JOUR
T1 - Safety of cilostazol in peripheral artery disease: A cohort from a primary healthcare electronic database
AU - Real, Jordi
AU - Serna, M. Catalina
AU - Giner-Soriano, Maria
AU - Forés, Rosa
AU - Pera, Guillem
AU - Ribes, Esther
AU - Alzamora, Maite
AU - Marsal, Josep Ramon
AU - Heras, Antonio
AU - Morros, Rosa
PY - 2018/5/8
Y1 - 2018/5/8
N2 - © 2018 The Author(s). Background: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users. Methods: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline during 2009-2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS). Results: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905 patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups. Conclusions: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients.
AB - © 2018 The Author(s). Background: Cilostazol has been associated with spontaneous reports of cardiovascular adverse events and serious bleeding. The objective of this study is to determine the relative risk of cardiovascular adverse events or haemorrhages in patients with peripheral artery disease treated with cilostazol in comparison to pentoxifylline users. Methods: Population-based cohort study including all individuals older than 40 who initiated cilostazol or pentoxifylline during 2009-2011 in SIDIAP database. The two treatment groups were matched through propensity score (PS). Results: Nine thousand one hundred twenty-nine patients met inclusion criteria and after PS matching, there were 2905 patients in each group. 76% of patients were men, with similar mean ages in both groups (68.8 for cilostazol and 69.4 for pentoxifylline). There were no differences in bleeding, cerebrovascular and cardiovascular events between both groups. Conclusions: Patients treated with cilostazol were different from those treated with pentoxifylline at baseline, so they were matched through PS. We did not find differences between treatment groups in the incidence of bleeding or cardiovascular and cerebrovascular events. Cilostazol should be used with precaution in elderly polymedicated patients.
KW - Arrhythmia
KW - Cardiovascular events
KW - Cilostazol
KW - Coronary artery disease
KW - Electronic health records
KW - Haemorrhage
KW - Pentoxifylline
KW - Peripheral artery disease
KW - Primary healthcare
UR - https://ddd.uab.cat/record/190813
U2 - https://doi.org/10.1186/s12872-018-0822-4
DO - https://doi.org/10.1186/s12872-018-0822-4
M3 - Article
VL - 18
JO - BMC Cardiovascular Disorders
JF - BMC Cardiovascular Disorders
SN - 1471-2261
IS - 1
M1 - 85
ER -